Which laboratory values indicate perimenopause and menopause?

Laboratory Values Indicating Perimenopause and Menopause

For menopause diagnosis, FSH and estradiol in the postmenopausal range combined with at least 12 months of amenorrhea (in women <60 years) are the key laboratory indicators, though menstrual history and age are more reliable than laboratory testing alone for perimenopause. 1

Menopause Laboratory Criteria

Definitive laboratory values for menopause include:

• FSH in the postmenopausal range (typically >25-30 IU/L, though specific ranges vary by assay) 1
• Estradiol in the postmenopausal range (typically <20-30 pg/mL) 1
• These values must be measured in women <60 years with ≥12 months of amenorrhea in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression 1

Age-based criteria that do not require laboratory confirmation:

• Age ≥60 years automatically qualifies as postmenopausal without laboratory testing 1
• Prior bilateral oophorectomy confirms postmenopausal status regardless of hormone levels 1

Perimenopause Laboratory Findings

Laboratory testing is notably unreliable during perimenopause because hormone levels fluctuate markedly during this transition. 2, 3, 4

Characteristic hormonal patterns in perimenopause include:

• Elevated FSH levels (range of means 4-32 IU/g creatinine), significantly higher than reproductive-aged women but lower than postmenopausal women 4
• Elevated LH levels (range of means 1.4-6.8 IU/g creatinine) compared to younger women 4
• Paradoxically elevated estradiol levels in many cases, with overall mean estrone conjugate excretion higher than younger women (76.9 vs 40.7 ng/mg creatinine) 5, 4
• Decreased progesterone/pregnanediol in the luteal phase (range 1.0-8.4 vs 1.6-12.7 μg/mg creatinine/luteal phase in younger women) 4

Critical limitation: FSH and estradiol measurements are unreliable guides to menopausal status during the transition because levels vary markedly cycle-to-cycle and even within cycles. 2, 3

Special Circumstances Requiring Laboratory Confirmation

Women taking tamoxifen or toremifene and age <60 years require FSH and estradiol levels in postmenopausal ranges to confirm menopausal status, as these medications interfere with clinical assessment. 1

Women with chemotherapy-induced amenorrhea cannot be reliably assessed by amenorrhea alone, as ovarian function may remain intact or resume despite absent menses; serial FSH and/or estradiol measurements are needed if aromatase inhibitor therapy is being considered. 1

Women receiving LHRH agonists or antagonists cannot have menopausal status assigned by any laboratory test, as these medications artificially suppress ovarian function. 1

Women with hysterectomy and retained ovaries (age ≤60 years) require LH, FSH, and serum estradiol in postmenopausal ranges measured prior to initiation of any systemic therapy. 1

Emerging Markers (Not Yet Standard)

Anti-Müllerian hormone (AMH) shows promise as a marker of ovarian reserve and may predict menopause proximity, but is not currently recommended for routine diagnosis due to lack of standardized cutoffs and age-specific reference ranges. 1

Inhibin B levels decline with falling follicle numbers and may be elevated (LR+ 2.05), but are not sufficiently accurate for clinical diagnosis. 2, 3

Clinical Approach

The optimal diagnostic strategy prioritizes clinical assessment over laboratory testing:

• For perimenopause: Diagnose based on menstrual history (irregular cycles, 3-11 months amenorrhea) and age (typically 40-55 years) without relying on laboratory results 2
• For menopause: Use age ≥60 years OR age <60 years with ≥12 months amenorrhea plus confirmatory FSH/estradiol only when needed for treatment decisions (e.g., aromatase inhibitor eligibility) 1

Common pitfall: Ordering FSH/estradiol during perimenopause when symptoms and menstrual irregularity are sufficient for diagnosis; these tests add little value and may be misleading due to hormonal fluctuations. 2, 3